142 related articles for article (PubMed ID: 35191990)
1. Comment on "Durability of response to primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel: OLYMPUS trial final report".
Song Y; Du Y; Qin C; Xu T
World J Urol; 2022 May; 40(5):1251-1252. PubMed ID: 35191990
[No Abstract] [Full Text] [Related]
2. Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report.
Matin SF; Pierorazio PM; Kleinmann N; Gore JL; Shabsigh A; Hu B; Chamie K; Godoy G; Hubosky SG; Rivera M; O'Donnell M; Quek M; Raman JD; Knoedler JJ; Scherr D; Weight C; Weizer A; Woods M; Kaimakliotis H; Smith AB; Linehan J; Coleman J; Humphreys MR; Pak R; Lifshitz D; Verni M; Klein I; Konorty M; Strauss-Ayali D; Hakim G; Seltzer E; Schoenberg M; Lerner SP
J Urol; 2022 Apr; 207(4):779-788. PubMed ID: 34915741
[TBL] [Abstract][Full Text] [Related]
3. Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial.
Kleinmann N; Matin SF; Pierorazio PM; Gore JL; Shabsigh A; Hu B; Chamie K; Godoy G; Hubosky S; Rivera M; O'Donnell M; Quek M; Raman JD; Knoedler JJ; Scherr D; Stern J; Weight C; Weizer A; Woods M; Kaimakliotis H; Smith AB; Linehan J; Coleman J; Humphreys MR; Pak R; Lifshitz D; Verni M; Adibi M; Amin MB; Seltzer E; Klein I; Konorty M; Strauss-Ayali D; Hakim G; Schoenberg M; Lerner SP
Lancet Oncol; 2020 Jun; 21(6):776-785. PubMed ID: 32631491
[TBL] [Abstract][Full Text] [Related]
4. Re: Primary Chemoablation of Low-grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-containing Reverse Thermal Gel (OLYMPUS): An Open-label, Single-arm, Phase 3 Trial.
Ourfali S; Colombel M
Eur Urol; 2021 Jan; 79(1):162. PubMed ID: 32891427
[No Abstract] [Full Text] [Related]
5. An evaluation of UGN-101, a sustained-release hydrogel polymer-based formulation containing mitomycin-C, for the treatment of upper urothelial carcinomas.
Porta C; Giannatempo P; Rizzo M; Lucarelli G; Ditonno P; Battaglia M
Expert Opin Pharmacother; 2020 Dec; 21(18):2199-2204. PubMed ID: 32870051
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of UGN-101, a mitomycin-containing reverse thermal gel instilled via retrograde catheter for the treatment of low-grade upper tract urothelial carcinoma.
Shabsigh A; Kleinmann N; Smith AB; Scherr D; Seltzer E; Schoenberg M; Lerner SP
Cancer Chemother Pharmacol; 2021 Jun; 87(6):799-805. PubMed ID: 33677615
[TBL] [Abstract][Full Text] [Related]
7. Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial.
Chevli KK; Shore ND; Trainer A; Smith AB; Saltzstein D; Ehrlich Y; Raman JD; Friedman B; D'Anna R; Morris D; Hu B; Tyson M; Sankin A; Kates M; Linehan J; Scherr D; Kester S; Verni M; Chamie K; Karsh L; Cinman A; Meads A; Lahiri S; Malinowski M; Gabai N; Raju S; Schoenberg M; Seltzer E; Huang WC
J Urol; 2022 Jan; 207(1):61-69. PubMed ID: 34433303
[TBL] [Abstract][Full Text] [Related]
8. The ablative effect of mitomycin reverse thermal gel: Expanding the role for nephron preservation therapy in low grade upper tract urothelial carcinoma.
Kaimakliotis HZ; Tachibana I; Woldu S; Labbate C; Jacob J; Murray K; Rose K; Sexton W; Dickstein R; Linehan J; Nieder A; Bjurlin M; Humphreys M; Ghodoussipour S; Quek M; O'Donnell M; Eisner BH; Matin SF; Lotan Y; Feldman AS
Urol Oncol; 2023 Sep; 41(9):387.e1-387.e7. PubMed ID: 37246135
[TBL] [Abstract][Full Text] [Related]
9. Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Woldu SL; Labbate C; Murray KS; Rose K; Sexton W; Tachibana I; Kaimakliotis H; Jacob J; Dickstein R; Linehan J; Nieder A; Bjurlin MA; Humphreys M; Ghodoussipour S; Quek ML; O'Donnell M; Eisner BH; Feldman AS; Matin SF; Lotan Y
Urol Oncol; 2023 Mar; 41(3):147.e15-147.e21. PubMed ID: 36424224
[TBL] [Abstract][Full Text] [Related]
10. Route of Administration for UGN-101 and Impact on Oncological and Safety Outcomes.
Linehan J; Gottlieb J; Woldu SL; Labbate C; Rose K; Sexton W; Kaimakliotis H; Jacob J; Dickstein R; Nieder A; Bjurlin M; Humphreys M; Ghodoussipor S; Quek M; O'Donnell M; Eisner BH; Feldman AS; Matin SF; Lotan Y; Murray KS
Eur Urol Focus; 2023 Nov; 9(6):1052-1058. PubMed ID: 37263827
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy After Complete Endoscopic Management of Upper Tract Urothelial Carcinoma.
Labbate C; Woldu S; Murray K; Rose K; Sexton W; Tachibana I; Kaimakliotis H; Jacob J; Dickstein R; Linehan J; Nieder A; Bjurlin M; Humphreys M; Ghodoussipour S; Quek M; O'Donnell M; Eisner B; Feldman A; Lotan Y; Matin SF
J Urol; 2023 May; 209(5):872-881. PubMed ID: 36657029
[TBL] [Abstract][Full Text] [Related]
12. Antegrade Instillation of UGN-101 (Mitomycin for Pyelocalyceal Solution) for Low-Grade Upper Tract Urothelial Carcinoma: Initial Clinical Experience.
Rosen GH; Nallani A; Muzzey C; Murray KS
J Urol; 2022 Jun; 207(6):1302-1311. PubMed ID: 35130080
[TBL] [Abstract][Full Text] [Related]
13. Chemoablation in Urothelial Carcinoma: A Systematic Review and Future Perspectives.
Alsyouf M; Pierorazio P; Groegler J; Hu B
Urology; 2020 Oct; 144():28-37. PubMed ID: 32540302
[TBL] [Abstract][Full Text] [Related]
14. Urinary bladder melanosis associated with urothelial dysplasia and invasive urothelial carcinoma: a report of two cases.
Patel P; Gotto G; Kavanagh A; Al Bashir S; Bismar TA; Trpkov K
Anal Quant Cytopathol Histpathol; 2013 Oct; 35(5):294-300. PubMed ID: 24282911
[TBL] [Abstract][Full Text] [Related]
15. [An unusual variant of urothelial carcinoma: the "nested variant of urothelial carcinoma." Report of two cases].
Badoual C; Bergemer-Fouquet AM; Renjard L; Lefrancq T; Lesourd B; Belhiba H; Fetissof F; Vieillefond A
Ann Pathol; 1999 Apr; 19(2):119-23. PubMed ID: 10349476
[TBL] [Abstract][Full Text] [Related]
16. Radical cystectomy and chemotherapy on plasmacytoid variant bladder urothelial carcinoma.
Song Y; Qin C; Du Y; Xu T
World J Urol; 2022 Sep; 40(9):2353-2354. PubMed ID: 35543878
[No Abstract] [Full Text] [Related]
17. Antegrade administration of mitomycin gel for upper tract urothelial carcinoma via percutaneous nephrostomy tube: a multi-institutional retrospective cohort study.
Rose KM; Narang G; Rosen G; Labatte C; Dumitrascu CI; Campagna J; Yu A; Manley BJ; Spiess PE; Li R; Adibi M; Murray KS; Sexton WJ; Humphreys MR
BJU Int; 2023 Apr; 131(4):471-476. PubMed ID: 36285629
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant methods to improve results of local bladder irrigations by chemotherapy for NMIBC.
Freifeld Y; Dekel Y; Stein A
Curr Urol Rep; 2013 Apr; 14(2):71-7. PubMed ID: 23334670
[TBL] [Abstract][Full Text] [Related]
19. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
[TBL] [Abstract][Full Text] [Related]
20. Urinary bladder urachal remnants underlying papillary urothelial carcinoma.
Isotalo PA; Robertson SJ; Futter NG
Arch Pathol Lab Med; 2002 Oct; 126(10):1252-3. PubMed ID: 12385339
[No Abstract] [Full Text] [Related]
[Next] [New Search]
